Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting the PI3K pathway in cancer: are we making headway?
Filip Janků, Timothy A. Yap, Funda Meric‐Bernstam
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 5, pp. 273-291
Closed Access | Times Cited: 897

Showing 1-25 of 897 citing articles:

Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet, Robert Montal, Daniela Sia, et al.
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 10, pp. 599-616
Open Access | Times Cited: 1621
The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
Gerta Hoxhaj, Brendan D. Manning
Nature reviews. Cancer (2019) Vol. 20, Iss. 2, pp. 74-88
Open Access | Times Cited: 1507
RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore, Scott Rosenberg, Frank McCormick, et al.
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 8, pp. 533-552
Open Access | Times Cited: 810
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Giampaolo Bianchini, Carmine De Angelis, Luca Licata, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 2, pp. 91-113
Closed Access | Times Cited: 787
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Antonino Glaviano, Aaron Song Chuan Foo, Hiu Yan Lam, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 704
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
Joaquı́n Mateo, Debyani Chakravarty, Rodrigo Dienstmann, et al.
Annals of Oncology (2018) Vol. 29, Iss. 9, pp. 1895-1902
Open Access | Times Cited: 578
Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance
Meran Keshawa Ediriweera, Kamani Hemamala Tennekoon, Sameera R. Samarakoon
Seminars in Cancer Biology (2019) Vol. 59, pp. 147-160
Closed Access | Times Cited: 556
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian Tian, Xiaoyi Li, Jinhua Zhang
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 3, pp. 755-755
Open Access | Times Cited: 508
LncRNA‐mediated posttranslational modifications and reprogramming of energy metabolism in cancer
Yue‐Tao Tan, Jin‐Fei Lin, Ting Li, et al.
Cancer Communications (2020) Vol. 41, Iss. 2, pp. 109-120
Open Access | Times Cited: 487
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy
Devesh Tewari, Pooja Patni, Anusha Bishayee, et al.
Seminars in Cancer Biology (2019) Vol. 80, pp. 1-17
Closed Access | Times Cited: 470
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Boris Shorning, Manisha S. Dass, Matthew J. Smalley, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 12, pp. 4507-4507
Open Access | Times Cited: 449
Clear cell renal cell carcinoma ontogeny and mechanisms of lethality
Eric Jonasch, Cheryl L. Walker, W. Kimryn Rathmell
Nature Reviews Nephrology (2020) Vol. 17, Iss. 4, pp. 245-261
Open Access | Times Cited: 447
PI3K isoforms in cell signalling and vesicle trafficking
Benoît Bilanges, York Posor, Bart Vanhaesebroeck
Nature Reviews Molecular Cell Biology (2019) Vol. 20, Iss. 9, pp. 515-534
Closed Access | Times Cited: 420
mTOR: Role in cancer, metastasis and drug resistance
Avaniyapuram Kannan Murugan
Seminars in Cancer Biology (2019) Vol. 59, pp. 92-111
Closed Access | Times Cited: 394
Lactate: A Metabolic Driver in the Tumour Landscape
Luigi Ippolito, Andrea Morandi, Elisa Giannoni, et al.
Trends in Biochemical Sciences (2018) Vol. 44, Iss. 2, pp. 153-166
Closed Access | Times Cited: 389
Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
Chao Dong, Jiao Wu, Yin Chen, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 265
Tumor suppressor p53 and metabolism
Juan Liu, Cen Zhang, Wenwei Hu, et al.
Journal of Molecular Cell Biology (2018) Vol. 11, Iss. 4, pp. 284-292
Open Access | Times Cited: 250
Targeting fibrosis: mechanisms and clinical trials
Manyu Zhao, Liqun Wang, Mengzhu Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 246
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Qian Sun, Zhenya Hong, Cong Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 233
Translational genomics and recent advances in oral squamous cell carcinoma
Annie Wai Yeeng Chai, Kue Peng Lim, Sok Ching Cheong
Seminars in Cancer Biology (2019) Vol. 61, pp. 71-83
Closed Access | Times Cited: 217
Medulloblastoma in the age of molecular subgroups: a review
Kyle Juraschka, Michael D. Taylor
Journal of Neurosurgery Pediatrics (2019) Vol. 24, Iss. 4, pp. 353-363
Open Access | Times Cited: 209
FOXO transcription factor family in cancer and metastasis
Yannasittha Jiramongkol, Eric W.‐F. Lam
Cancer and Metastasis Reviews (2020) Vol. 39, Iss. 3, pp. 681-709
Open Access | Times Cited: 208
Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy
Faustino Mollinedo, Consuelo Gajate
Journal of Lipid Research (2020) Vol. 61, Iss. 5, pp. 611-635
Open Access | Times Cited: 202
Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors
Ariella B. Hanker, Virginia Kaklamani, Carlos L. Arteaga
Cancer Discovery (2019) Vol. 9, Iss. 4, pp. 482-491
Open Access | Times Cited: 199
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Rosalin Mishra, Hima Patel, Samar Alanazi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 7, pp. 3464-3464
Open Access | Times Cited: 198
Page 1 - Next Page

Scroll to top